|
Letters
September
13, 2002
Dockets Management
Branch
Food and Drug Administration
5630 Fishers Lane
Rockville, MD 20852
Docket No. 02N-0209 - Request for Comments on First Amendment
Issues
Introduction and Summary
The undersigned
Members of Congress strongly object to the Administration's apparent
intention to curtail FDA's ability to regulate promotional claims
for drugs and other health-related products. Each of us has a long-standing
commitment to advancing the public health and to ensuring that products
on which our citizens rely to protect their health are safe for
their intended uses, are adequately tested to demonstrate that they
are effective, and are not deceptively promoted.
The Federal
Food, Drug, and Cosmetic Act (FDCA) was enacted to protect consumers
from injurious and fraudulent foods and drugs, and it has been amended
several times over the past 75 years to expand its protections over
drugs, medical devices, and foods. The FDCA's restrictions on misleading
and unsubstantiated promotional claims are central to its goal of
preventing injury from dangerous and deceptive products. The Administration,
putting corporate interests ahead of consumer safety and cloaking
itself in the First Amendment, now appears ready to undermine the
core protections of the FDCA and to allow manufacturers to make
questionable and potentially dangerous claims about products that
intimately affect the health of all Americans.
Referring to
recent court decisions giving protection to "commercial speech"under
the First Amendment, a notice issued by FDA, dated May 16, 2002,
states that these decisions may be in conflict with the FDA's long-standing
implementation of the FDCA, and even with the Act itself. Despite
the absence of any current lawsuit challenging these requirements,
the leadership of the agency has taken it upon itself to suggest
that much of FDA's regulation of the promotional activities of food
and drug manufacturers is unconstitutional. The questions posed
at the end of the notice challenge the validity of one of the cornerstones
of the FDCA: the requirement that before marketing a new product
or a new use of a product intended to treat disease, a manufacturer
must demonstrate to FDA that the product is safe and effective for
its intended use. The notice appears to doubt that promotion of
unapproved medical products or unapproved uses causes sufficient
harm to justify its current level of regulation.
The notice
goes on to ask whether, under the First Amendment, the promotional
requirements now applicable to dietary supplements might not be
more appropriate for drugs. Using dietary supplement regulation
as a model would dramatically deregulate the marketing of prescription
drugs. The authors of the notice apparently believe that consumers
can be adequately protected from harm when manufacturers are free
to promote drugs for any use, whether substantiated or not. Under
a dietary supplement model, neither the safety nor the effectiveness
of these products would be subject to government review before marketing.
Manufacturers would instead be trusted to provide truthful, non-misleading
information about whatever evidence they have on the medical benefits
and risks of their products. And if a manufacturer should fail in
this responsibility, the market or FDA would somehow clean up the
mess after the claims were made and the product was in wide use.
The Administration
is contemplating action that flies in the face of almost a century
of documented harm to the lives and health of Americans from unrestricted
promotional claims about health-related products. Over the last
75 years, Congress has held numerous hearings documenting a long
and sometimes shameful legacy of deceptive and dangerous claims
made by manufacturers of products intended to improve health. As
shown in a wealth of Congressional documents, the history of the
FDCA demonstrates beyond question that without pre-market safety
and effectiveness requirements, deceptive, unsubstantiated claims
about health-related products proliferate, at a tremendous cost
in human lives. It also demonstrates that post-market actions against
misleading claims are incapable of protecting consumers from unsafe
and ineffective products.
Recognizing this history, and the critical importance of drugs,
medical devices, and foods to every American, the FDCA establishes
requirements to assure that medical products (drugs, biological
products, medical devices) are safe and effective. With the exception
of the least risky types of medical devices (e.g., tongue depressors),
the FDCA permits manufacturers to promote only those uses of their
products that have been first reviewed for safety and effectiveness
by FDA. It also requires that FDA review health claims for foods
and determine that they are supported by significant scientific
agreement. These requirements were enacted to serve the highest
governmental interest: protecting the lives and health of Americans.
A restriction
on commercial speech satisfies the First Amendment if it directly
advances a substantial government interest, Central Hudson Gas &
Elec. v. Public Serv. Comm'n., 447 U.S. 557 (1980), is based on
evidence of real harm and alleviates the harm to a material degree,
Edenfield v. Fane, 507 U.S. 761 (1993), and is narrowly tailored
to meet the desired ends, Board of Trustees v. Fox, 492 U.S. 469,
480 (1989). As described in detail in the body of this comment,
the evidence on which the promotional restrictions of the FDCA are
based more than satisfies the requirements of the Constitution.
Evidence
supporting premarket approval of safety. Before drug and device
companies were required to demonstrate the safety of their products
before approval, Congress had evidence that dangerous, sometimes
deadly, products abounded:
Widely
promoted weight loss products containing toxic ingredients caused
severe side effects, including blindness and death in young women;
An antibiotic produced by a reputable drug company, containing
an untested solvent, killed 107 Americans within a few weeks,
most of them children. The solvent was diethylene glycol, a component
of anti-freeze, and the company was unaware of its toxicity. Neither
full disclosure - e.g., "we know of no evidence of harm from
this product" - nor post-market vigilance - FDA immediately
sent out warnings and rounded up all remaining stores of the product
within days of the first reports of deaths - would have saved
the 107 victims; and
The
Dalkon Shield, an IUD, caused life-threatening infections and
robbed thousands of women of their fertility.
Evidence supporting premarket approval of effectiveness.
Before drug companies were required to demonstrate the effectiveness
of their products before approval, they were subject to a regime
much like that suggested by the Administration. They could make
any promotional claims about their products, as long as they were
truthful and not misleading. In practice, this regime led to unnecessary
injuries and deaths. Several years of hearings preceding the enactment
of the effectiveness requirement showed that:
The
pharmaceutical marketplace was filled with misleading promotional
claims;
The
use of ineffective drugs subjected patients to serious side effects
without any corresponding benefit and delayed or prevented effective
treatment for serious and life-threatening conditions;
Drugs with serious side effects, such as potent tranquilizers
and toxic antibiotics, were being widely promoted for minor conditions
and for vulnerable populations, such as pregnant women, resulting
in many injuries and deaths; and
After
the effectiveness requirement was imposed, the agency reviewed
the effectiveness of drugs already on the market. This review
established that 80 % of the uses for which drugs were promoted
lacked adequate evidence to show their effectiveness. One third
of all marketed drugs were ultimately removed from the market
because they were not effective for a single one of their promoted
indications;
Enforcement actions against these claims were futile because
they took months and sometimes years, while the products continued
to be promoted and to cause harm;
Intense promotion caused physicians to switch from older,
cheaper, and more effective drugs to newer, untested and sometimes
ineffective drugs;
Drugs were being promoted for indications far beyond the
evidence of their effectiveness and even for indications for which
they had been shown to be ineffective; drugs with serious side
effects were widely promoted for mild conditions;
It was impossible for physicians to ascertain which drugs
were effective and which were not. In the absence of an effectiveness
requirement, manufacturers rarely carried out adequate effectiveness
tests. Such evidence as existed was generally unpublished or scattered
through hundreds of medical journals of varying quality;
Such evidence
provided Congress with a more than adequate justification for its
conclusion that, in the absence of a requirement that manufacturers
demonstrate safety and effectiveness for each promoted use before
approval, Americans suffer great harm from the promotion of ineffective
and unsafe health-related products. There was also abundant evidence
to support the conclusion that alternatives, such as disclaimers
disclosing the state of the evidence supporting a claim, and post-market
enforcement actions, were inadequate to stop deceptive and dangerous
products. The record revealed that when there is no requirement
to conduct the tests necessary to establish safety and effectiveness,
such tests are rarely conducted. Disclaimers cannot in any way address
the grave harm to patients caused by a marketplace in which no one
is sure which products work and which do not: many patients are
denied effective treatment while others risk serious side effects
without any benefit that would justify the risk. Post-market enforcement
actions are cumbersome and time-consuming and leave consumers unprotected
from dangerous products for months and even years. This evidence
is equally relevant to the regulation of drugs, biological products,
medical devices, and foods promoted to treat diseases. There is
thus more than adequate evidence to sustain the constitutionality
of the promotional restrictions currently in place under the FDCA.
Although the May 16 notice calls into question the constitutionality
of several important statutory requirements, the notice also states
that "FDA intends to defend the act against any constitutional
challenges . . ." We will be watching closely to be sure that
the agency lives up to its promise. We believe that defending and
enforcing its governing statute is the only appropriate course for
FDA. We are deeply concerned at the suggestion that FDA will cease
enforcing key regulations, or even statutory requirements, because
the agency's current leadership believes they violate the First
Amendment. Our concern is heightened because the agency has chosen
to take the broadest possible interpretation of court decisions
limiting restrictions on commercial speech (see FDA letter to Senator
Reed, attached), when narrower interpretations that would preserve
FDA's authority are legally sound. Insisting on such a broad interpretation
suggests a deliberate intention to undermine FDA's critical public
health activities.
The attempt
to restrict FDA's authority over promotional claims is particularly
offensive when the agency is operating without a Congressionally
confirmed Commissioner. The Administration apparently contemplates
stripping a vital public health agency of crucial powers while it
is without a leader who has met the requirements of Congressional
confirmation. It is unacceptable for the Administration to implement
far-reaching, anti-consumer policies through an appointee whose
qualifications to make decisions directly affecting the health of
our citizens have never been subjected to Congressional scrutiny.
We demand that
no further action be taken pursuant to this notice until FDA has
a confirmed Commissioner.
II.
A History of Harm from Unsubstantiated and Deceptive Claims
The questions
posed at the end of the May 16 notice question the validity of one
of the cornerstones of the FDCA: the requirement that before marketing
a new drug or a new use of a drug, a manufacturer must obtain FDA
approval by showing that the drug is safe and effective for its
intended use. (Although not stated, the safety and effectiveness
requirements for biological products and medical devices are implicitly
questioned as well.) The notice suggests that there is inadequate
support for the conclusion that promotion of unapproved drugs or
unapproved uses is inherently misleading or that it causes sufficient
harm to justify its strict regulation. It suggests further that
consumers can be adequately protected from dangerous and deceptive
products through (1) court actions to stop false or misleading claims,
after they have been made; and (2) disclaimers.
The history
of the FDCA is unfortunately replete with evidence that the regulatory
scheme envisioned by the authors of the notice is inadequate to
protect consumers from harm and carries a huge cost in human lives.
In fact, at different times in history, the FDCA has looked much
like the scheme envisioned by the Administration. Before 1938, drugs
could be marketed without pre-market approval for safety or effectiveness.
After many Americans died from inadequately tested drugs, Congress
required in 1938 that drugs be approved for safety, but not effectiveness.
Manufacturers could promote their products for any use and were
trusted to make promotional claims that were truthful and not misleading.
If FDA concluded that the claims were false or misleading, it was
required to undertake an enforcement action to stop the claims.
When experience revealed that manufacturers were promoting drugs
for uses for which they were ineffective and even dangerous, Congress
required in1962 that drugs be approved for safety and effectiveness
before marketing. This history has provided to Congress a revealing
study of the behavior of the marketplace when there are no or limited
premarket approval requirements for drugs and other medical products
and of the public health consequences of this behavior. Congressional
oversight of the FDCA has demonstrated beyond question that without
premarket safety and effectiveness requirements, deceptive and unsubstantiated
claims about medical products proliferate, at tremendous cost to
the public health. It has also amply demonstrated that promotion
of unapproved uses is inherently misleading and that alternatives
such as post-market enforcement actions cannot protect consumers
from the harm caused by false and misleading promotional claims.
A. The Evidence
Supporting Premarket Approval of Safety
The 1906 Pure
Food and Drug Act contained no premarket approval requirements.
It permitted FDA to take action against already-marketed drugs that
it could prove were adulterated in certain ways. Congress first
required that drugs be approved for safety in 1938, after five years
of Congressional hearings showing that, under the limited post-market
authority of the 1906 Act, consumers were being widely exposed to
dangerous and fraudulent drugs. Congressional hearings into drugs
being widely promoted for treatment of obesity showed that many
of these drugs were hazardous when used for weight loss and that
many people had been hurt. One such agent, promoted as exceptionally
effective, was Dinitrophenol, a compound used in the manufacture
of explosives. This compound has more recently been used as an herbicide
and insecticide and is now known to be extremely toxic to humans
and animals. Over 100,000 Americans responded to the promotional
claims for Dinitrophenol, and suffered skin rashes, cataracts, blindness,
and in some cases, death. Hearings showed that many other extremely
dangerous drugs were widely promoted for various diseases.
Congress' decision
to require pre-market approval for safety was finally prompted by
the Elixir Sulfanilamide disaster in 1937. Over 100 people, most
of them children, died after taking an antibiotic being marketed
by a S. E. Massengill, Inc., a reputable drug company. At the time,
the FDCA did not require that drug ingredients be studied for safety
before marketing and the company had added an untested solvent to
create a liquid version of the drug for children. The solvent was
diethylene glycol, a component of anti-freeze, and parents watched
their children die slow and painful deaths. Massengill denied responsibility
for the deaths and FDA was able to charge the company only with
a minor labeling infraction.
Congress concluded
that pre-market approval for safety was essential to prevent future
incidents like these. It would be irresponsible to claim that a
pre-market safety requirement for drugs is an unnecessary burden
on First Amendment rights, in the face of this history. The accumulated
evidence was more than sufficient to conclude that lesser restrictions,
such as full disclosure or strong post-marketing enforcement, would
not have prevented another Elixir Sulfanilamide disaster. Because
it was not required to test for safety, Massengill did not know
of the toxicity of diethylene glycol. Therefore, a requirement that
the company provide a true statement of the information available
about the product e.g., "we know of no evidence of harm
from this product"-- would have protected no one. Nor could
prompt action by FDA, once the toxicity was known, have saved the
victims. In the actual event, as soon as physicians began to report
the deaths from Elixir Sulfanilamide, FDA investigators, together
with State and local officials, immediately conducted a massive
search for all remaining stocks of the drug, quickly recovering
all but a small amount of the finished product. During this short
period of time, 107 people died.
B. The Evidence
Supporting Premarket Approval for Effectiveness
The 1906 Pure
Food and Drug Act allowed FDA to take action against false labeling
claims made about products, but only if the agency could prove intentional
fraud. If the manufacturer showed an honest belief in his product,
FDA could take no action. In hearings leading up to the passage
of the 1938 Act, Congress heard testimony from FDA that Banbar,
a product widely promoted for diabetes, was ineffective, and that
many diabetic patients were taking it instead of insulin, the only
effective treatment for diabetes. FDA had tracked down many of the
patients taking Banbar and learned that a large number had died
after abandoning their insulin. FDA brought an enforcement action
against the maker of Banbar but lost the case, because the agency
couldn't prove deliberate fraud.
In response
to evidence of cases like this, Congress in 1938 modified the law
to permit FDA to bring cases against products promoted with false
and misleading claims, regardless of whether the manufacturer committed
deliberate fraud. Congress did not require that drugs be shown to
be effective in 1938; it took the lesser step of requiring that
claims be truthful and not misleading. Pub. L. No. 75-717, 52 Stat.1040,
§502. For the next 24 years, the U.S. pharmaceutical marketplace
operated under a system much like that suggested in the FDA notice.
Manufacturers could promote their products for any uses as long
as their claims were not false or misleading. If FDA believed that
claims were false or misleading, it had the burden of demonstrating
this to a court, while the product was already on the market.
1. Evidence
from House and Senate Hearings in the 1950's and 1960's
Beginning in
the 1950's and extending into the early 1960's, both the House and
Senate held extensive hearings on the drug industry. A large part
of these hearings focused on the false and misleading promotion
of drugs by the pharmaceutical industry. False and Misleading Advertising
(Weight Reducing Preparations), Hearings Before a Subcommittee of
the Committee on Government Operations, House of Representatives,
85th Cong. 1st Sess. (1957); False and Misleading Advertising (Prescription
Tranquilizing Drugs), Hearings Before a Subcommittee of the Committee
on Government Operations, House of Representatives, 85th Cong. 2d
Sess. (1958); Administered Prices, Drugs, S. Rep. No. 448, 87th
Cong., 1st Sess. 171 (1961); The Drug Industry Antitrust Act, Hearings
before the Antitrust Subcommittee of the Committee on the Judiciary,
87th Cong. 2d Sess (1962); Drug Industry Act of 1962, Hearings before
the House Committee on Interstate and Foreign Commerce, 87th Cong.
2d Sess. (1962).
The evidence
developed from these hearings demonstrated that a regulatory scheme
that depended on post-market enforcement against false and misleading
promotion was grossly inadequate to protect Americans from serious
harm. The hearings showed that the pharmaceutical marketplace was
filled with misleading promotional material on which physicians
relied, that there was no reliable source of evidence from which
physicians could tell effective drugs from ineffective drugs, and
that many Americans were being unnecessarily subjected to toxic
drugs whose benefits had been greatly exaggerated or were non-existent.
Public health experts, physicians, and experts in drug pharmacology
testified that:
Hundreds
of new drugs were being introduced each year, many of them minor
modifications of existing products or combinations of existing
drugs, but promoted as significant breakthroughs;
Drugs
were being promoted for indications far beyond any responsible
evidence of their effectiveness and even for indications for which
they were known to be ineffective;
Intense promotion of these drugs caused physicians to switch
from older, cheaper, and more effective drugs to new, but untested
drugs; a considerable period usually elapsed before it became
widely known that a highly advertised new drug fell short of its
claims;
When
an ineffective drug was prescribed, it usually replaced an older
but effective drug, subjecting patients to side effects without
benefits and to lack of effective treatment for serious and even
life-threatening conditions;
Drugs
with serious side effects, such as potent tranquilizers and anti-psychotic
drugs, were being widely promoted for minor conditions and for
vulnerable populations, such as pregnant women;
Physicians
were being inundated with promotional material from drug companies
that was misleading and unreliable, often in subtle ways;
Post-market
enforcement actions against misleading claims were almost always
futile because they took "months or even years," while
the drugs stayed on the market causing harm. An FTC report showed
that actions against misleading advertising completed between
1955 and 1957 took from several months up to 9 years. By the time
the misleading claim was finally eliminated, the company had switched
to a new, often equally misleading claim.
"Educational" efforts by detailmen, widely used
by the pharmaceutical companies to promote products out of sight
of regulatory scrutiny, and relied on more heavily by physicians
than any other source of drug information, were misleading physicians
about the true merits of prescription drugs;
In
the absence of an effectiveness requirement, manufacturers rarely
carried out adequate effectiveness tests of their products;
It
was impossible for physicians to ascertain which drugs were effective
for their claimed uses because of the large number of drugs being
introduced, misleading advertising, the absence of adequate effectiveness
testing, the fact that the evidence, if there was any, was either
unpublished or scattered through hundreds of medical journals,
and the lack of time and training most physicians have to devote
to the study of detailed clinical reports;
There
was no reliable source of information to which physicians could
turn when trying to assess the effectiveness of a drug; and
Huge
expenditures on promotion and on development of minor modifications
of existing drugs left little room for development of new drugs
for significant health problems.
A later review
by the National Academy of Sciences of drugs on the market before
1962 showed that Congress's concerns about widespread promotion
of ineffective drugs were more than justified. Over 80 % of the
uses for which drugs were promoted before 1962 were found to lack
adequate evidence of effectiveness. One third of all drugs (1,099
of 3,443) on the market in 1962 could not be shown to be effective
for a single indication and were taken off the market. These included
widely promoted drugs that were among the top 200 in sales. A
large percentage of the remaining drugs lost one or more of the
indications for which they had been previously marketed.
2. Specific
Examples of Harm
The hearings
leading up to the enactment of an effectiveness requirement identified
several specific types of harm to which Americans were being daily
subjected from this tide of ineffective and over-promoted drugs.
One was promotion of toxic drugs for uses for which the drugs' benefits
did not outweigh their risks. For example, the antibiotic chloramphenicol
(Chloromycetin) was widely promoted for a wide range of uses, from
life-threatening to minor infections. When cases of aplastic anemia,
a serious, sometimes fatal blood disorder, were shown to be caused
by chloramphenicol, FDA required the company to include warnings
in the drug's label and both FDA and the AMA recommended that the
drug's uses be restricted. These warnings about serious and even
fatal adverse reactions failed to slow demand, however. Documents
provided in Congressional hearings showed that detailmen continued
to promote the drug as effective for a wide range of uses and to
downplay the warnings, resulting in widespread use of the drug for
minor infections, and an unnecessary toll of serious adverse reactions
and deaths.
Congress heard
testimony that drug companies promoted tranquilizers for every type
of psychological distress from serious depression to mild anxiety,
and added them to a variety of other drugs, from heart disease medications
to gastrointestinal drugs. Even mild tranquilizers can be addictive,
while many others cause serious, often irreversible side effects.
Tranquilizers were later shown to be ineffective in all of the combination
products and unsafe or ineffective for most of the remaining uses
for which they were promoted. Thus, consumers were subjected to
serious injuries that outweighed any possible benefit.
Some of the
widely promoted tranquilizers were in fact powerful anti-psychotic
drugs with side effects so severe they are now used only for the
treatment of serious mental illnesses like schizophrenia and manic-depression.
Librium, a drug now reserved for manic-depression, was advertised
for the pregnant woman "who imagines that she is having birth
pains 6 months ahead of her time," and for the "surgical
patient who sees doom in the frown of a nurse." An ad for Thorazine,
now reserved for schizophrenia, in the Maryland State Medical Journal
for July 1962 showed "a beautiful picture of a happy family,
with the caption-
Emotional
control regained*** a family restored *** thanks to a doctor and
Thorazine *** Experience in over 14 million Americans *** A fundamental
drug in both office and hospital practice.'"
Thorazine was
already known to cause agranulocytosis, a depletion of white blood
cells that is frequently fatal. One expert testified that he had
personally seen 11 cases of agranulocytosis and 4 deaths from over-prescription
of Thorazine.
Mellaril, now
a drug of last resort for schizophrenia because of its severe side
effects, including sudden death, was widely promoted to general
practitioners for pregnant women with emotional symptoms in connection
with childbirth, and "tense, nervous patients seen in everyday
practice * * * for chronic fatigue, insomnia, anxiety, and apprehension,
vague digestive disorders, etc." An expert testified that he
was "impressed with that etc.' It just tapers off into
the wide, blue yonder where tranquilizers are claimed to be good
for everything." Both Thorazine and Mellaril also cause tardive
dyskinesia, a serious and sometimes irreversible movement disorder,
in which the patient suffers from involuntary and disfiguring movements
of the face, tongue, and neck. The severe risks associated with
these drugs could never justify their use for such minor conditions
as everyday tension or insomnia, and yet that is exactly what they
were promoted for in a setting where there was no effectiveness
requirement for each promoted use.
These examples
illustrate the public health damage that results from a system that
approves medical products for safety but not effectiveness, or that
permits promotional claims about uses for which the product has
not been demonstrated to be effective to regulators. Because drugs
have potentially serious risks, a drug can be considered safe only
when its risks are outweighed by its benefits for particular uses.
A drug with significant side effects may be considered safe if it
is known to be effective in the treatment of a serious condition,
but may be unacceptably harmful for a minor condition or even for
another serious condition when the drug's benefits for that condition
have not been established. Because safety and effectiveness are
inextricably related, it is meaningless to say that a drug is "safe"
except in relation to a specific demonstrated benefit. Almost no
drug can be considered safe for uses for which it has no demonstrated
benefits.
There were
also examples of ineffective drugs promoted for serious conditions,
where other treatments were available. Deprol, a tranquilizer was
promoted to general practitioners for all types of depression, including
serious depression. A psychiatric expert testified that there was
no evidence that Deprol was effective for depression, and that the
vigorous promotion of Deprol caused him deep concern about the fate
of depressed patients seen by general practitioners. The Secretary
of Health, Education, and Welfare testified about the widespread
promotion of Clarin for heart disease, despite an AMA determination
that the drug lacked effectiveness.
A final example
illustrates the grave harm that can befall patients when drugs do
not have to be shown to be effective before marketing. In the 1940's
and 50's, diethylstilbestrol (DES) was widely promoted to prevent
threatened spontaneous abortion (miscarriage). Because DES was considered
safe and effective, it was also prescribed for normal pregnancies.
It has been estimated that between 5 and 10 million American women
received DES before FDA issued a warning against its use in pregnant
women in 1971. In 1970, evidence began to accumulate that exposure
to DES in utero caused a high rate of reproductive abnormalities
in the daughters and sons of women given DES, including hundreds
of cases in girls and young women of a rare form of vaginal cancer
previously found only in elderly women. Among the reproductive injuries
caused by DES, daughters of women who took DES have an increased
rate of premature births, casting the shadow of DES toxicity over
the next generation. Perhaps the greatest tragedy of DES is that
years after it was first marketed, an independent study showed that
it was completely ineffective for preventing miscarriages. Even
after this study was published, the drug continued to be prescribed
for pregnant women.
Had there been
an effectiveness requirement in place when DES was introduced, thousands
of men and women would have been spared the serious, sometimes fatal
injuries caused by the drug. Of course the terrible side effects
of the drug were not known at the time the drug was prescribed.
But that is the nature of drugs: as countless examples demonstrate,
their true toxicity is often not known until many thousands or millions
of people have been exposed. Knowing this to be true, it is unconscionable
to expose patients to drugs without a well-established benefit for
each promoted use.
3. Unsubstantiated
Promotional Claims Shown to be Inherently Misleading
The evidence
accumulated by Congress before passage of the 1962 Amendments to
the FDCA demonstrated that, without benefit of pre-market review
of a drug's effectiveness by an objective body, it was simply not
possible for most physicians to discern which products were effective
and which were not. Three features of the pre-1962 scheme caused
promotional claims about unproven uses to be considered inherently
misleading: (1) physicians relied heavily on promotional information
from manufacturers, much of which was misleading; (2) what reliable,
objective evidence existed was difficult or impossible for average
physicians to find because they were too busy to track down scattered,
often unpublished data on hundreds of new drugs; and (3) in the
absence of required testing, few, if any, companies conducted the
kind of studies that would provide reliable evidence of their products'
effectiveness. In this setting, only academic specialists had the
knowledge and time to ferret out the truth about drug products within
their specialities. Even then, there were few, if any, definitive
studies on the effectiveness of marketed drugs, leaving the experts
to guess which drugs were effective and which were not.
In the world
envisioned by the May 16 notice, physicians are somehow able to
make rational prescribing decisions based primarily on promotional
material from manufacturers and in the absence of access to well-designed,
objective studies of effectiveness. As the Secretary of HEW testified
in 1962, however, it is meaningless to say that a physician should
have the right to decide for himself whether a drug is effective,
unless "truthful and complete information" about the effectiveness
of a drug is available to any physician in the ordinary course of
practice. The marketplace as it existed before there was an effectiveness
requirement provided neither. For most physicians, "truthful"
information was impossible to separate from misleading information,
and "complete information" was almost never available.
Truthful information
was impossible to separate from misleading information because promotional
material cited scientific evidence in ways that made harried physicians
believe they had adequate information to make prescribing decisions.
One expert testified about the "exceedingly subtle" methods
employed in promotional material to convey the impression that claims
were supported by scientific evidence, when, in fact, there was
no little or no support for the claims. He provided a representative
ad that cited seven references to demonstrate the scientific support
for the advertised claims. When the expert took the time to look
into these references, not one could be shown to support the claims
in the ad. The first and third cited studies were "in press"
and unavailable for review, the second study was uncontrolled and
its results had been distorted in the ad, the fourth study was clearly
misrepresented, and the fifth, sixth, and seventh references were
"personal communications" with the company and unavailable
for review. The expert also presented data on a larger review of
prescription drug advertising which showed that the problems seen
in his example were commonplace. In addition, he found that (1)
negative studies (studies that failed to show that the drug worked)
were never reported in promotional material; (2) data were presented
as if they were of high scientific quality when in fact they were
not; (3) studies cited were frequently from low quality or foreign
publications; and (4) statements and findings in studies were taken
out of context. Many other experts testified that promotional material
appeared to provide scientific support that was in fact lacking,
but in ways that would be difficult for the average physician to
detect.
Hearings on
advertising of over-the-counter drugs showed that promotion to consumers
was at least as misleading as that to physicians.
Where the evidence
showed that physicians and consumers had no access to objective
information about the effectiveness of drugs and neither the time
nor the knowledge to pin down the truthfulness of promotional material,
it was entirely appropriate for Congress to consider such material
inherently misleading.
4. Other
Restrictions Shown to Be Inadequate to Prevent Harm
The notice
suggests that rules against false and misleading claims and/or disclaimers
could provide adequate protection to consumers from dangerous and
deceptive products, and that prohibiting promotion of unapproved
uses is therefore unconstitutional. To the contrary, Congress had
more than enough evidence to find that neither of these methods
could protect consumers.
When Congress imposed effectiveness requirements on drugs and devices,
it had abundant evidence that a rule against false and misleading
advertising coupled with post-market enforcement actions was ineffective
in protecting consumers from harm. As described above, the major
thrust of five years of hearings was a demonstration that this very
regulatory regime failed to stop the promotion of deceptive and
dangerous products. As one public health expert testified:
"It is
not sufficient to say that some law in some book presently forbids
some of these practices. Long before governmental authorities are
in a position to prove the illegality of these practices and get
the cumbersome legal machinery into motion and remove the drug from
the market, grave harm has been done.
"This
evil can only be remedied, we believe, in a fair and practical way
by putting the burden where it belongs, on the manufacturers of
these potent drugs, by requiring them to demonstrate the efficacy
and safety of their products."
The Secretary
of HEW, too, testified that the absence of an effectiveness requirement
left consumers unprotected from harmful products and that reliance
on post-market actions against misleading advertising had proven
itself to be "indefensible":
"Even
if the FDA has reason to believe that [a] new drug is not effective
for the purposes claimed, it must approve the new drug application
once the requirements of safety have been met. Then the manufacturer
is at liberty to promote his product. If claims for effectiveness
are made which the FDA believes are groundless, a proceeding must
then be brought to take the drug off the market as a misbranded
product. At that point the burden of proof is on the FDA to establish
that the drug is not effective. And throughout the period of time
it takes for the FDA to prepare its case and secure relief in the
courts, the manufacturer will have foisted his product upon an unsuspecting
public.
" . .
. . We believe that where public health is involved it is intolerable
to permit the marketing of worthless products under the rules of
a cat-and-mouse game where a manufacturer can fool the public until
the Food and Drug Administration finally catches up with him."
The May 16
notice also suggests that disclaimers might be adequate replacements
for a demonstration of safety or effectiveness. The record before
Congress is more than sufficient to demonstrate the fallacy that
disclaimers can broadly protect consumers from unsafe and ineffective
products to improve health. A disclaimer could take many forms,
but the two most obvious forms are (1) a required statement that
the government has not reviewed the claim; and (2) a statement created
by the manufacturer ostensibly providing adequate information for
a consumer to assess the weight of the evidence supporting a claim,
e.g., "some studies suggest that this product is effective
while others are inconclusive." In a variation of the second
type of disclaimer, FDA might issue a regulation specifying types
of information that must be in a disclaimer or specifying other
details of presentation. The drafting of specific disclaimers would
still be the responsibility of the manufacturer, and, in absence
of pre-market review of claims, FDA would still be required to initiate
an enforcement action if it believed the disclaimer violated the
regulation or was otherwise misleading.
The first type
of disclaimer would provide precisely the information known to every
physician before 1962: at that time, as everyone knew, the government
did not review the effectiveness of drugs. This knowledge, however,
did not in any way assist physicians in determining which products
would help their patients and which would not, because that information
was generally unavailable. Thus, a disclaimer stating that a claim
had not been reviewed by FDA would provide no useful information
to a physician about whether to prescribe the drug and would offer
her patients no protection from unsafe or ineffective products,
or from the harm that can flow from such products (described in
detail above).
The second
type of disclaimer relies on the manufacturer to disclose the true
state of the scientific evidence supporting a claim. As the record
before Congress amply demonstrated, in the absence of pre-market
safety and effectiveness requirements, many companies fail to conduct
adequate tests of their products' safety or effectiveness. Once
again, when there is little or no reliable evidence to support a
claim, a disclaimer, no matter how truthful, cannot help physicians
determine which products will provide treatment for their patients
and which will not. The harm that flows from a marketplace in which
there is no reliable evidence on the effectiveness of the products
physicians must prescribe for their patients was described in great
detail in the Congressional hearings preceding the 1962 Amendments
to the FDCA.
Moreover, both
those hearings and subsequent hearings on drug advertising repeatedly
showed that, in the absence of government review, many companies
fail to provide, in promotional material, an objective presentation
of the evidence supporting their products. There is ample evidence
that information provided to doctors by pharmaceutical companies
continues to lack objectivity. There is no more reason to expect
these companies to provide a truthful, non-misleading disclaimer
than there is to expect that the promotional claims themselves will
be truthful and non-misleading.
5. Permitting
Promotion of Unapproved Uses Eliminates the Incentive to Establish
Effectiveness
One possible
interpretation of the May 16 notice is that the current FDA leadership
believes that there is a sufficient basis to require manufacturers
to establish the safety and effectiveness of the first use of a
new product, but that, after the first approval, manufacturers should
be free to promote additional uses of their products without FDA
approval. The legislative history of the 1962 Amendments to the
FDCA and the statute itself could not be clearer that Congress intended
manufacturers of drugs to establish the effectiveness of each new
use before marketing. Nevertheless, the May 16 notice questions
this statutory requirement and asks for evidence that permitting
manufacturers to promote unapproved uses would undermine the requirement
that they obtain approval for these uses. Not only is it abundantly
clear that permitting promotion of unapproved uses would undermine
the requirement that these uses be approved, but the legislative
history recited above provides ample evidence of the harm that flows
from unrestricted promotion of products for new unapproved uses.
First, the
legislative history shows that when products can be promoted for
unapproved uses, manufacturers frequently advertise them for uses
that are unsubstantiated, for uses that do not justify the risks
posed by the drugs, and for uses for which older drugs are more
effective. Promotion of unapproved uses has been shown to subject
patients to serious side effects without corresponding benefits
and to denial or delay of effective treatment. See sections II.B.1
and 2, above. The evidence adequately demonstrates that neither
post-market enforcement actions nor disclaimers can protect patients
from these consequences of promotion of unapproved uses. See section
II.B.4. For these reasons alone, Congress had adequate evidence
to conclude that a prohibition on promotion of unapproved new uses
was necessary to alleviate real harm, and that lesser restrictions
were inadequate to address the harm.
Second, it
is clear that permitting products to be promoted for unapproved
uses would undermine the requirement that new uses be approved.
We believe that it is self-evident that many, if not most, manufacturers
of new medical products permitted to promote freely their products
for unapproved uses would decide, on economic grounds, not to undertake
the considerable and unnecessary expense of obtaining FDA approval
for new uses. Gaining the right to promote new uses is the only
substantial incentive manufacturers have to obtain FDA approval.
Even if it were not self-evident, the pre-1962 marketplace provides
a sufficiently revealing model of whether, when permitted to promote
freely their products for any use, manufacturer undergo the expense
of conducting adequate and well-controlled studies (the standard
for FDA approval) of their products' effectiveness. Many, if not
most, do not. See section II.B.1. As the post-1962 NAS/NRC review
of the effectiveness of marketed drugs showed, 80% (4 out of 5)
of the uses for which drugs were promoted were not supported by
reliable evidence of effectiveness. Thus, the long-standing prohibition
against promotion of unapproved new uses is an adequately justified
restriction on commercial speech.
6. Biological
products, medical devices, and foods promoted to treat disease.
The evidence
of harm from unrestricted promotion of drugs applies equally
to other medical products and to foods promoted for treatment of
disease. The pre-1962 hearings showed how manufacturers of prescription
drugs behave where there is no requirement that they establish the
effectiveness of each use of their products: many of them engage
in deceptive promotion of products whose effectiveness has not been
established and whose risks outweigh their benefits. Manufacturers
of medical devices and biological products market products with
identical purposes and market them to precisely the same audiences
as drug manufacturers. Their incentives to promote truthfully or
deceptively are the same as those of drug manufacturers. Food manufacturers
who seek to promote their products to prevent or treat diseases
have similar incentives. The only significant difference between
food manufacturers who promote their products to prevent or treat
disease and drug manufacturers is that food manufacturers promote
primarily to consumers, an audience with less ability than physicians
to weigh the scientific evidence supporting claims.
The evidence
from the prescription drug marketplace that Americans are harmed
by promotion of products that have not been approved for effectiveness
is therefore applicable to biological products, medical devices,
and foods. The evidence that post-market enforcement actions and
disclaimers cannot protect consumers from harm is equally relevant.
III. Conclusion
Our country's
long-standing requirements that medical products be shown to be
safe and effective before marketing are well-justified. They are
supported by decades of experience and thousands of pages of Congressional
documents showing the grave harm to the public health that follows
unrestricted promotion of health-related products.
The May 16
notice suggests that FDA would like to cease enforcing many of the
promotional restrictions of the FDCA. The agency is apparently contemplating
this action because its current leadership believes that under the
First Amendment, the only way that the agency may protect the public
health is to trust the pharmaceutical industry not to make deceptive
or dangerous promotional claims about its products. This conclusion
is unsound as a matter of law, and disastrous as a matter of public
policy. If there has been any lesson that we have learned in the
last year from the accumulation of corporate accounting scandals,
it is that even some of the largest and most successful corporations
in America are capable of abusing the public trust. When corporate
wrongdoers placed short-term profits ahead of the truth in accounting,
millions of Americans lost their jobs and their savings. If we remove
some of our most important requirements on promotion of products
to improve health, and corporations do not live up to their obligation
to promote them objectively and truthfully, many Americans could
lose their lives.
In conclusion,
the detailed record of past abuses by those marketing products to
improve health is more than sufficient to justify the constitutionality
of the current protections. These restrictions were enacted to prevent
repetition of real harm to American lives and were based on evidence
that lesser restrictions had failed to prevent these harms. FDA
has no basis under the First Amendment for failing to enforce the
current limitations on promotion of health-related claims. No further
action on the May 16 notice should be taken until FDA has a Congressionally
confirmed Commissioner with adequate qualifications to make decisions
of this importance to the public health.
Signed:
Edward M.. Kennedy
United States Senate
Henry A. Waxman
United States House of Representatives
Richard J.
Durbin
United States Senate
Sherrod Brown
United States House of Representatives
Charles Schumer
United States Senate
Rosa L. DeLauro
United States House of Representatives
Louise Slaughter
United States House of Representatives
Marcy Kaptur
United States House of Representatives
Tom Allen
United States House of Representatives
|